Zhu Lu, Liu Binkai, Hu Yang, Wang Molin, Furtado Jeremy D, Rimm Eric B, Grandjean Philippe, Sun Qi
Department of Nutrition, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, MA, 02115, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, MA, 02115, USA.
Environ Health. 2024 Dec 3;23(1):108. doi: 10.1186/s12940-024-01147-2.
Existing evidence for associations of per- and polyfluoroalkyl substances (PFASs) with blood lipids, lipoproteins and apolipoproteins (apo), and coronary heart disease (CHD) risk is limited and inconsistent. This study aims to explore associations between plasma PFASs, blood lipoprotein subspecies defined by apolipoproteins, and CHD risk.
A case-control study of CHD was conducted in the Health Professionals Follow-Up Study (HPFS) and Nurses' Health Study (NHS). Among participants initially free of cardiovascular disease at blood collection in 1994 (HPFS) or 1990 (NHS), 101 participants who developed non-fatal myocardial infarction or fatal CHD were identified and confirmed. A healthy control was matched to each case for age, smoking status, and date of blood draw. Plasma levels of perfluorohexane sulfonic acid (PFHxS), perfluorooctanoic acid (PFOA), total perfluorooctane sulfonic acid (PFOS), branched PFOS (brPFOS), linear PFOS (nPFOS), perfluorononanoic acid (PFNA), and perfluorodecanoic acid (PFDA) were measured. Conditional logistic regression and cubic spline regression models were used to examine associations between baseline PFASs and CHD risk. Linear regression models were applied to study PFAS associations with lipids and their subfractions.
After multivariate adjustments, total PFOS, brPFOS and nPFOS were significantly associated with increased risk of developing CHD, and HRs (95% CIs) per log(ng/mL) increment of PFASs were 3.66 (1.36-9.89), 3.68 (1.55-8.76), and 3.01 (1.16-7.86), respectively. Significant positive dose-response relationships were identified for these PFASs (P = 0.01, 0.002, 0.02, respectively). Other PFASs were not associated with CHD risk. PFNA and PFDA were positively associated with total apoE levels among HDL particles with or without apoC-III. No associations were observed for other PFASs with blood lipid subspecies. Blood lipid subfractions did not explain the association between PFOS and CHD risk.
Plasma PFOS and its isomers were positively associated with CHD risk. These findings suggest that PFOS exposure causes public health risks that are greater than hitherto believed.
关于全氟和多氟烷基物质(PFASs)与血脂、脂蛋白和载脂蛋白(apo)以及冠心病(CHD)风险之间关联的现有证据有限且不一致。本研究旨在探讨血浆PFASs、由载脂蛋白定义的血液脂蛋白亚类与CHD风险之间的关联。
在健康专业人员随访研究(HPFS)和护士健康研究(NHS)中进行了一项CHD病例对照研究。在1994年(HPFS)或1990年(NHS)采血时最初无心血管疾病的参与者中,确定并确认了101例发生非致命性心肌梗死或致命性CHD的参与者。为每个病例匹配一名年龄、吸烟状况和采血日期均匹配的健康对照。测量了全氟己烷磺酸(PFHxS)、全氟辛酸(PFOA)、总全氟辛烷磺酸(PFOS)、支链PFOS(brPFOS)、直链PFOS(nPFOS)、全氟壬酸(PFNA)和全氟癸酸(PFDA)的血浆水平。使用条件逻辑回归和三次样条回归模型来检验基线PFASs与CHD风险之间的关联。应用线性回归模型研究PFASs与脂质及其亚组分之间的关联。
经过多变量调整后,总PFOS、brPFOS和nPFOS与发生CHD的风险显著相关,PFASs每增加log(ng/mL) 1个单位,HRs(95% CIs)分别为3.66(1.36 - 9.89)、3.68(1.55 - 8.76)和3.01(1.16 - 7.86)。这些PFASs呈现出显著的正剂量反应关系(P分别为0.01、0.002、0.02)。其他PFASs与CHD风险无关。PFNA和PFDA与有或无apoC-III的HDL颗粒中的总apoE水平呈正相关。未观察到其他PFASs与血脂亚类之间存在关联。血脂亚组分无法解释PFOS与CHD风险之间的关联。
血浆PFOS及其异构体与CHD风险呈正相关。这些发现表明,PFOS暴露所带来的公共健康风险比迄今所认为的更大。